Menu
Recruiting NCT06511232

Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction

Phase IV Interventional Anterior Cruciate Ligament Tear Anterior Cruciate Ligament Injuries Anterior Cruciate Ligament Rupture

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Intraosseous Morphine.
Who it may be relevant to
Registry conditions: Anterior Cruciate Ligament Tear, Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture. Basic parameters: 18 years — 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction: A Randomized Control Trial

Overview

The purpose of this study is to determine if intraosseous (IO) morphine decreases pain and post-operative opioid use in patients undergoing anterior cruciate ligament (ACL) reconstruction.

Interventions

  • Drug Intraosseous Morphine
    More recently, intraosseous infusion of analgesics and antibiotics has gained traction in the total joint arthroplasty literature. In knee arthroplasty patients, the combination of a spine and adductor canal block with an intraosseous infusion of morphine into the tibial tubercle prior to incision yielded lower pain in the immediate postoperative period and at 2 weeks, less pain medication use, and significantly better patient-reported outcomes while also reducing systemic opioid exposure in the

Primary outcome measures

  • Patient Pain Levels in the Post-Operative Period as assessed by a patient-reported post operative symptom journal. [Time frame: 2 weeks postop, 6 weeks postop, 12 weeks postop]
  • Changes in Post-Operative Opioid Use [Time frame: 2 weeks postop]
  • Patient Pain Levels in the Post-Operative Period as assessed by the Lysholm Knee Survey [Time frame: 2 weeks postop, 6 weeks postop, 12 weeks postop]
Secondary outcome measures (3)
  • Patient Range of Motion in the Post-Operative Period as assessed by the KOOS, JR Knee Survey [Time frame: Preop, 2 weeks postop, 6 weeks postop, 12 weeks postop]
  • Patient Activity Level in the Post-Operative Period as assessed by the Tegner scale. [Time frame: Preop, 2 weeks postop, 6 weeks postop, 12 weeks postop]
  • Patient Range of Motion in the Post-Operative Period as assessed by the Lysholm Knee Survey [Time frame: 2 weeks postop, 6 weeks postop, 12 weeks postop]

Eligibility criteria

Inclusion criteria

  • Patients of the IRB approved surgeon(s) undergoing ACL reconstruction with bone-to-bone (BTB) autograft
  • Patients aged between 18-40 years old at the time of surgery

Exclusion criteria

  • Patients undergoing ACL reconstruction with any other type of autograft or allograft other than BTB
  • Patients younger than 18 years old or older than 40 years old
  • Patients undergoing meniscal root repair or any other repair that changes their weight-bearing status
  • Patients with a history of substance abuse
  • Vulnerable populations
  • Patients on chronic pain medication within the last 6 months
  • BMI >/= 35
  • Allergy to morphine
  • Unwilling to participate
  • Any additional reason the PI deems reasonable

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Houston Methodist Research Institute — Houston

Identifiers

NCT: NCT06511232 · PRO00037918

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗